Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

Mutated COVID-19 variant C.1.2 elicits concern

By Brian Buntz | August 30, 2021

coronavirus COVID-19 Pfizer

[Photo by Fusion Medical Animation on Unsplash]

As even countries with substantial vaccination rates such as the U.S., U.K. and Israel continue to fight the Delta variant, a new threat appears to have emerged in South Africa.

First spotted in South Africa, the C.1.2 variant is potentially more infectious and resistant to antibodies than Delta. Scientists continue to study the variant’s potential to infect the vaccinated and unvaccinated.

Scientists first spotted C.1.2 in Mpumalanga and Gauteng, two provinces in Eastern South Africa.

Outside of South Africa, researchers have identified the variant in other African nations, New Zealand, the U.K. and mainland Europe.

Also troubling is that the C.1.2 variant is mutating at a rate of 41.8 mutations annually — 1.7 times the rate of other variants of concern, according to a preprint study published in MedRxiv.

Another MedRxiv preprint, however, estimated that the C.1.2 variant is mutating at the rate of 26.6 substitutions per year.

The former study estimates that the C.1.2 variant is between 44 and 59 mutations removed from the Wuhan Hu-1 viral strain that launched the pandemic.

Still, C.1.2 is not wholly new. It shares several mutations found in the Alpha, Beta, Delta and Gamma variants of SARS-CoV-2. It also contains mutations found in the Kappa, Eta and Lambda variants of interest.

The CDC listing of SARS-CoV-2 Variant Classifications and Definitions currently does not have an entry for the C.1.2 variant.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Pfizer logo
Pfizer CEO tests positive for COVID-19
Pfizer logo
Pfizer and BioNTech seek EMA authorization for COVID-19 vaccination in young children
Pfizer logo
FDA allows pharmacists to prescribe Paxlovid 
vaccine
Will COVID-19 vaccines be updated by fall? 

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards